Terns Pharmaceuticals, Inc. – NASDAQ:TERN

Add to watchlist

$6.31

+0.54

+9.36%

Market closed

Open in 3 days

-38.02%

month

-38.02%

quarter

-13.88%

year

Market Cap	486.27M
Enterprise value	281.35M

P/E	-7.12
EV/Sales	N/A
EV/EBITDA	-3.27
Price/Sales	N/A
Price/Book	1.52
PEG ratio	-0.29
EPS	-1.26

Revenue	N/A
EBITDA	-102.95M
Income	-91.05M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Terns Pharmaceuticals Stock Forecast

M Q Y

Last Year

$18.67

Potential upside: 195.82%

Analysts Price target
Financials & Ratios estimates

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Profit margin
Jun 2023	0	-17.89M
Sep 2023	0	-29.76M
Dec 2023	1.32M	-21.01M	-1589.94%
Mar 2024	0	-22.37M

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Debt to assets
Jun 2023	289697000	15.54M	5.37%
Sep 2023	271687000	13.26M	4.88%
Dec 2023	268517000	13.15M	4.9%
Mar 2024	246766000	10.04M	4.07%

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Cash Flow
Jun 2023	-12.99M	-90.83M	489K
Sep 2023	-20.69M	-22.31M	20K
Dec 2023	-19.31M	47.23M	13.86M
Mar 2024	-22.79M	7.99M	0

Terns Pharmaceuticals alternative data

Terns Pharmaceuticals
Employees

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Employee count
Aug 2023	46
Sep 2023	46
Oct 2023	46
Nov 2023	46
Dec 2023	46
Jan 2024	46
Feb 2024	46
Mar 2024	66
Apr 2024	66
May 2024	66
Jun 2024	66
Jul 2024	66

Terns Pharmaceuticals
Hedge Funds Holdings Q1 2023

55.09% -44.91%

of TERN is owned by hedge funds

36 -29

hedge funds hold TERN stock

19.84M -29.87M

shares is hold by hedge funds

TERN hedge funds holdings changes

Terns Pharmaceuticals
Insider Trading

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Insider trades (number of shares)
Period	Buy	Sel
Apr 2024	0	420663
May 2024	9582	0
Jul 2024	0	127093
Aug 2024	0	15000
Sep 2024	476190	27235
Dec 2024	15450	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	5 Dec 2024	BURROUGHS AMY L. director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	15,450	$7.15	$110,468
Purchase	12 Sep 2024	LU HONGBO director director	Common Stock	285,714	$10.5	$2,999,997
Purchase	12 Sep 2024	LU HONGBO director director	Common Stock	190,476	$10.5	$1,999,998
Option	10 Sep 2024	VIGNOLA MARK J. officer: Chief Fi..	Common Stock	10,000	$5.36	$53,600
Sale	10 Sep 2024	VIGNOLA MARK J. officer: Chief Fi..	Common Stock	10,000	$11	$110,000
Option	10 Sep 2024	VIGNOLA MARK J. officer: Chief Fi..	Stock Option (Right to Buy)	10,000	$5.36	$53,600
Option	9 Sep 2024	QUIGLEY JILL M. director director	Common Stock	17,235	$1.82	$31,368
Sale	9 Sep 2024	QUIGLEY JILL M. director director	Common Stock	17,235	$10	$172,350
Option	9 Sep 2024	QUIGLEY JILL M. director director	Stock Option (Right to Buy)	17,235	$1.82	$31,368
Sale	2 Aug 2024	QUIGLEY JILL M. director director	Common Stock	8,857	$7.5	$66,436

TERN insider trading transactions

Terns Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Senthil Vel Sundaram (1978) Chief Executive Officer & Director	47	$581,770
Dr. Erin Quirk M.D. (1971) Head of R&D, Pres & Chief Medical Officer	54	$549,390
Dr. Mark Joseph Vignola (1978) Chief Financial Officer & Treasurer	47	$402,150

Terns Pharmaceuticals
Latest News

Wednesday, 4 December 2024
13:18	Terns's stock soars as analysts cheer leukemia data — and predict more gains	marketwatch.com
Tuesday, 3 December 2024
16:35	Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer	https://thefly.com
08:01	Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial	marketwatch.com
Monday, 2 December 2024
16:05	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)	globenewswire.com
Monday, 18 November 2024
16:05	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors	globenewswire.com
Monday, 7 October 2024
16:05	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)	globenewswire.com
Wednesday, 25 September 2024
10:30	Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst	seekingalpha.com
Wednesday, 18 September 2024
10:07	This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments	fool.com
Sunday, 15 September 2024
07:21	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.	fool.com
06:09	Should You Invest in This Under-the-Radar Weight Loss Stock?	fool.com
Saturday, 14 September 2024
10:12	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More	fool.com
Friday, 13 September 2024
13:30	Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic	seekingalpha.com
Thursday, 12 September 2024
19:00	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	globenewswire.com
Tuesday, 10 September 2024
22:50	Terns Announces Pricing of Upsized $150.15 Million Public Offering	globenewswire.com
12:31	Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug	zacks.com
10:25	Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive	seekingalpha.com
Monday, 9 September 2024
16:01	Terns Announces Proposed Public Offering	globenewswire.com
09:58	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill	barrons.com
09:12	Top 2 Health Care Stocks That May Collapse This Quarter	benzinga.com
07:48	Terns Pharmaceuticals' stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form	marketwatch.com
07:34	Terns Pharmaceuticals' oral obesity drug cuts weight by 4.9% in early study	reuters.com
07:05	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity	globenewswire.com
Tuesday, 3 September 2024
09:00	Terns Surges 29.6% in Three Months: Will the Momentum Continue?	zacks.com
Wednesday, 28 August 2024
10:57	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet	zacks.com
Friday, 2 August 2024
13:54	3 Biotech Stocks That Could Have Investors Grinning Soon	investorplace.com
Monday, 29 July 2024
16:05	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition	globenewswire.com
Saturday, 20 July 2024
09:30	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?	fool.com
Friday, 21 June 2024
18:30	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation	globenewswire.com
Wednesday, 19 June 2024
14:31	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?	zacks.com
Tuesday, 4 June 2024
10:56	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade	zacks.com

Ideas & Opinions

Seeking Alpha 11 Jul 2025

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Seeking Alpha 30 Apr 2024

Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
Seeking Alpha 9 Oct 2023

Terns Pharmaceuticals: Business Model Does Not Impress
Seeking Alpha 20 Jul 2023

Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth
Seeking Alpha 30 Mar 2023

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
Seeking Alpha 21 Mar 2023

Terns Pharmaceuticals: Early-Stage Biopharma Worthy Of Your Attention

Frequently Asked Questions (FAQ)

What's the price of Terns Pharmaceuticals stock today?

One share of Terns Pharmaceuticals stock can currently be purchased for approximately $6.31.
When is Terns Pharmaceuticals's next earnings date?

Unfortunately, Terns Pharmaceuticals's (TERN) next earnings date is currently unknown.
Does Terns Pharmaceuticals pay dividends?

No, Terns Pharmaceuticals does not pay dividends.
How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals has a market capitalization of 486.27M.
What is Terns Pharmaceuticals's stock symbol?

Terns Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TERN".
What is Terns Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Terns Pharmaceuticals?

Shares of Terns Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Terns Pharmaceuticals's key executives?
Terns Pharmaceuticals's management team includes the following people:
- Mr. Senthil Vel Sundaram Chief Executive Officer & Director(age: 47, pay: $581,770)
- Dr. Erin Quirk M.D. Head of R&D, Pres & Chief Medical Officer(age: 54, pay: $549,390)
- Dr. Mark Joseph Vignola Chief Financial Officer & Treasurer(age: 47, pay: $402,150)
How many employees does Terns Pharmaceuticals have?

As Jul 2024, Terns Pharmaceuticals employs 66 workers.
When Terns Pharmaceuticals went public?

Terns Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
What is Terns Pharmaceuticals's official website?

The official website for Terns Pharmaceuticals is ternspharma.com.
Where are Terns Pharmaceuticals's headquarters?

Terns Pharmaceuticals is headquartered at 1065 East Hillsdale Boulevard, Foster City, CA.
How can i contact Terns Pharmaceuticals?

Terns Pharmaceuticals's mailing address is 1065 East Hillsdale Boulevard, Foster City, CA and company can be reached via phone at +65 05255535.
What is Terns Pharmaceuticals stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Terns Pharmaceuticals in the last 12 months, the avarage price target is $18.67. The average price target represents a 195.82% change from the last price of $6.31.

Terns Pharmaceuticals, Inc.

ternspharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

+65 05255535

1065 East Hillsdale Boulevard
Foster City, CA 94404

CIK: 0001831363
ISIN: US8808811074
CUSIP: 880881107